Myelodysplastic Syndrome Treatment Market, by Drug (Lenalidomide, Decitabine, Azacitidine, and Phase 3 Drugs), by Route of Administration (Injection and Oral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030
Myelodysplastic syndromes are a group of cancers in which immature blood cells in the bone marrow do not mature or become healthy blood cells. The different types of myelodysplastic syndromes are diagnosed based on certain changes in the blood cells and bone marrow. Myelodysplastic syndromes (MDS) are a type of rare blood cancers where don't have enough healthy blood cells. It is also known as myelodysplasia. There are several different types of MDS. In MDS, some of the cells in the bone marrow are abnormal (dysplastic) and have problems making new blood cells. Several of the blood cells formed by these bone marrow cells are defective. Defective cells often die earlier than normal cells, and the body also destroys some abnormal blood cells, leaving the person without enough normal blood cells. Different cell types can be affected, although the most common finding in Myelodysplastic syndromes is a shortage of red blood cells (anemia). Therapy-related MDS is a subtype of Myelodysplastic syndromes. It is caused by treatment with chemotherapy or radiation therapy for a previous cancer. In the U.S., the number of new diagnoses of Myelodysplastic syndromes and therapy-related Myelodysplastic syndromes are both rising. This is because older people make up a growing segment of the population and people now live longer after treatment for cancer.
Market Dynamics
Increasing launch and approval of Azacitidine in key regions namely North America, Latin America, Europe, Asia Pacific, and Africa etc. is expected to drive growth of Azacitidine segment of the myelodysplastic syndrome treatment market over the forecast period. For instance, in February 2018, BeiGene, Ltd. Biotechnology Company announced the commercial availability of VIDAZ (azacitidine for injection) in China. VIDAZA is approved in China for patients with intermediate-2 / high-risk myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) with 20-30% bone marrow blasts, and chronic myelomonocytic leukemia (CMML). It is marketed in China by BeiGene under an exclusive license from Celgene Corporation (Pharmaceutical Company).
Key features of the study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook